Low Level Enantiomeric Impurity Analysis Using the ACQUITY UPC2 System

Importance of the Topic

Chiral purity is crucial for pharmaceutical agents because enantiomeric impurities can affect efficacy and safety. The analysis of trace-level enantiomers ensures compliance with regulatory standards and supports the development of single-enantiomer drug substances.

Objectives and Study Overview

This study demonstrates rapid separation and quantification of R- and S-benzyl mandelate enantiomers using the ACQUITY UPC2 System. It aims to achieve detection of 0.02% impurity levels and high reproducibility in enantiomeric excess determination within minimal analysis time.

Methodology and Instrumentation

• Stationary phase: CHIRALPAK AD-H, 4.6 × 150 mm, 5 µm
• Mobile phase composition: CO2 and methanol in a 70:30 ratio
• Flow rate: 4 mL/min
• Back pressure: 120 bar
• Column temperature: 40 °C
• Injection volume: 5 µL
• Analyte concentration: 0.20 mg/mL for each enantiomer
• Total analysis time: <1.5 min

Used Instrumentation

• ACQUITY UPC2 System equipped for UltraPerformance Convergence Chromatography
• Optimized UV detector for enhanced sensitivity

Key Results and Discussion

At 0.20 mg/mL, the system separated R- and S-benzyl mandelate with retention times of 0.93 and 1.34 min, respectively. Repeatability was excellent: retention time RSD <0.23% and peak area RSD <0.5%. The detector achieved an S/N ratio of approximately 3 for the minor enantiomer at 0.02% relative concentration, enabling quantification and an enantiomeric excess (e.e.) determination of 99.96%. Chromatograms were generated in under 1.5 minutes, highlighting the speed of analysis.

Benefits and Practical Applications

• Rapid chiral screening supports high-throughput environments
• Enhanced sensitivity meets stringent regulatory impurity thresholds
• High reproducibility ensures reliable quality control and QA/QC
• Applicable to diverse chiral drug intermediates and active substances

Future Trends and Potential Applications

Advancements in supercritical fluid chromatography will likely focus on expanding chiral stationary phase libraries, integrating mass spectrometric detection for structural confirmation, and automating method development. These trends will further streamline enantiomeric impurity profiling in pharmaceutical R&D and manufacturing.

Conclusion

The ACQUITY UPC2 System delivers fast, reproducible, and sensitive analysis of enantiomeric impurities at low levels. Its performance supports regulatory compliance and accelerates chiral method development for drug substances.

References

• Waters Corporation. Low Level Enantiomeric Impurity Analysis Using the ACQUITY UPC2 System. Application Note 720004245EN. 2012.